Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kezar Life Sciences, Inc. KZR
$2.59
-$0.01 (-0.58%)
На 18:01, 12 мая 2023
+575.68%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
189254349.00000000
-
week52high
11.02
-
week52low
2.25
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.17402900
-
EPS
-1.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 авг 2022 г. |
| Wells Fargo | Overweight | Overweight | 28 июн 2022 г. |
| Wells Fargo | Overweight | Overweight | 13 мая 2022 г. |
| Wells Fargo | Overweight | Overweight | 04 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 мар 2022 г. |
| Wells Fargo | Overweight | Overweight | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Morningside Venture Investments Ltd | D | 5512993 | 50000 | 02 февр 2023 г. |
| Morningside Venture Investments Ltd | D | 5562993 | 40000 | 01 февр 2023 г. |
| Morningside Venture Investments Ltd | D | 5602993 | 30000 | 31 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5632993 | 30000 | 30 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5662993 | 50000 | 25 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5712993 | 80000 | 24 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5792993 | 80000 | 23 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5872993 | 6114 | 17 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5879107 | 1971 | 13 янв 2023 г. |
| Morningside Venture Investments Ltd | D | 5881078 | 5000 | 12 янв 2023 г. |
Новостная лента
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Business Wire
04 янв 2023 г. в 16:01
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.
Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold
Seeking Alpha
16 ноя 2022 г. в 01:23
Following a shift in market sentiment, I've narrowed my rating for Kezar Life Sciences from buy to hold. The market has heavily discounted KZR's growth catalysts of clinical trial updates and regulatory tailwinds.
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology's Kidney Week 2022 Annual Meeting
Business Wire
14 окт 2022 г. в 07:00
SOUTH SAN FRANCISCO, Calif.
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
Business Wire
29 сент 2022 г. в 16:05
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 – 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
Business Wire
01 сент 2022 г. в 07:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Thursday, S